MADRID · 23–27 OCT 2026

Breast Cancer
Programme

ESMO 2026 public schedule, arranged for quick mobile reference. Madrid local time.

Congress details & attendance
VENUE · 23–27 OCT 2026 IFEMA Madrid · Madrid, Spain

Av. del Partenón 5, 28042 Madrid, Spain

Open in Maps ↗
95official BC topics
14presentation sessions
9industry satellite sessions
95 official BC presentations · grouped by Session

Official ESMO presentation-topic filter: Advanced BC, advanced stage, early stage, locally advanced, HER2+, HR+ and triple-negative BC. Open a Session to see its topics; the official Session link contains the corresponding speaker and presentation-level timing.

Invasive lobular carcinoma: Detecting and managing an elusive enemyFri 23 Oct · 13:30–14:45 · Cordoba Auditorium – Hall 4 · 6 topics
  1. Presentation of case/condition
  2. Overview of lobular breast cancer (incl biology)
  3. Medical oncology perspective
  4. Radiology perspective
  5. Pharmacology perspective
  6. Q&A and discussion
Official Session agenda, speakers & timing ↗
Proffered paper 1: Breast cancer, early and advanced stageFri 23 Oct · 13:30–15:00 · Alicante Auditorium – Hall 6 · 10 topics
  1. Invited Discussant LBA23, LBA13 and LBA27
  2. Q&A and discussion
  3. Invited Discussant LBA24, LBA25 and LBA50
  4. Q&A and discussion
  5. LBA13 – Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer: HORIZON-Breast06
  6. LBA23 – Final results of TALENT: T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
  7. LBA24 – Final Analysis of NRG Oncology/NSABP B-42 extended letrozole in hormone-receptor-positive breast cancer
  8. LBA25 – Adjuvant ribociclib + NSAI in HR+/HER2− early breast cancer: NATALEE 6-year OS and efficacy outcomes
  9. LBA27 – APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer
  10. LBA50 – PANKU-Breast01: izalontamab brengitecan in previously treated HR+/HER2− locally advanced or metastatic BC
Official Session agenda, speakers & timing ↗
Rapid oral: Breast cancer, early stageFri 23 Oct · 16:15–17:45 · Alicante Auditorium – Hall 6 · 13 topics
  1. Invited Discussant 544RO, 538RO and 539RO
  2. Invited Discussant 540RO, 541RO and 542RO
  3. Invited Discussant 543RO, LBA28 and 545RO
  4. Q&A and discussion
  5. 538RO – Patient-reported outcomes from lidERA: giredestrant in ER-positive, HER2-negative early BC
  6. 539RO – Patient-reported outcomes from DESTINY-Breast05: T-DXd versus T-DM1 in high-risk HER2-positive early BC
  7. 540RO – Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage TNBC: B-STRONGER-I
  8. 541RO – HR, PDL1 and sTILs predict pembrolizumab benefit in HER2-positive early BC: neoHIP
  9. 542RO – Prognostic impact of postoperative ctDNA surveillance in high-risk breast cancer: JCOG1204A1
  10. 543RO – DESTINY-Breast11: MRI-assessed responses during neoadjuvant T-DXd followed by THP versus ddAC-THP
  11. 544RO – Final GIM3 FATA analysis: treatment schedule and three aromatase inhibitors in postmenopausal HR-positive early BC
  12. 545RO – Omission of adjuvant radiotherapy after breast-conserving surgery in older ER-positive patients: TOP-1 5-year results
  13. LBA28 – Compression therapy using normal-sized surgical gloves for prevention of paclitaxel-induced neuropathy: AIUR trial
Official Session agenda, speakers & timing ↗
Proffered paper 2: Breast cancer, early and advanced stageSat 24 Oct · 08:30–10:00 · Alicante Auditorium – Hall 6 · 10 topics
  1. Invited Discussant LBA51, LBA14 and 1842O
  2. Q&A and discussion
  3. Invited Discussant LBA26, LBA96 and LBA15
  4. Q&A and discussion
  5. 1842O – Atirmociclib + fulvestrant after prior CDK4/6 inhibitor: FOURLIGHT-1
  6. LBA14 – Fulvestrant and ipatasertib in HER2-negative, ER-positive metastatic BC: CCTG/BCT MA.40/FINER OS results
  7. LBA15 – Anbenitamab plus albumin-bound docetaxel in HER2-positive advanced BC
  8. LBA26 – Short-term preoperative durvalumab for stage I TNBC: UNLOCK 14 / POP-DURVA
  9. LBA51 – KEYNOTE-B49: pembrolizumab plus chemotherapy in HR+/HER2− advanced BC
  10. LBA96 – First-line datopotamab deruxtecan versus chemotherapy in metastatic TNBC: TROPION-Breast02 brain-metastases analysis
Official Session agenda, speakers & timing ↗
Rapid oral 1: Breast cancer, advanced stageSat 24 Oct · 10:15–11:45 · Almeria Auditorium – Hall 9 · 10 topics
  1. Invited Discussant LBA16, 1RO and 2RO
  2. Invited Discussant LBA17 and 3RO
  3. Invited Discussant 1RO and 1766RO
  4. Q&A and discussion
  5. 1RO – Overall survival from postMONARCH: abemaciclib + fulvestrant after prior CDK4/6 inhibitor
  6. 2RO – Biomarker analyses from evERA BC: giredestrant + everolimus post-CDK4/6 inhibitor
  7. 3RO – 18F-FES PET-defined whole-body ER heterogeneity predicts endocrine responsiveness in ER+/HER2− metastatic BC
  8. 1766RO – HRQoL from HER2CLIMB-05: tucatinib maintenance in HER2+ metastatic BC
  9. LBA16 – VIKTORIA-1 updated results: gedatolisib + fulvestrant ± palbociclib in HR+/HER2− advanced BC
  10. LBA17 – HER2-PET imaging to predict T-DXd efficacy: PREDICT-HER
Official Session agenda, speakers & timing ↗
Optimising treatment for triple negative early breast cancerSat 24 Oct · 14:45–16:15 · Almeria Auditorium – Hall 9 · 5 topics
  1. Optimising systemic therapy and sequence for stage I TNBC
  2. Neoadjuvant therapy for TNBC
  3. Incorporation of PARP inhibitors
  4. What to do after optimal neoadjuvant therapy?
  5. Q&A and discussion
Official Session agenda, speakers & timing ↗
Novel concepts for metastatic breast cancer: Looking to the futureSat 24 Oct · 16:30–18:00 · Barcelona Auditorium – Hall 9 · 5 topics
  1. How can we incorporate combination strategies in early drug development?
  2. Next generation therapies
  3. How to monitor biomarkers and ctDNA
  4. Tailoring therapy for patients with exceptional disease response
  5. Q&A and discussion
Official Session agenda, speakers & timing ↗
Personalising treatment for patients with early stage HR+ breast cancerSun 25 Oct · 08:30–10:00 · Bilbao Auditorium – Hall 3 · 5 topics
  1. Clinical staging and characterization: upfront surgery versus neoadjuvant therapy
  2. Who needs chemotherapy with or without immunotherapy in 2026: who, when and how?
  3. Refining endocrine therapy with CDK4/6 inhibitors in early breast cancer
  4. Tailoring axillary management
  5. Q&A and discussion
Official Session agenda, speakers & timing ↗
Optimising treatment for HER2+ early breast cancerSun 25 Oct · 10:15–11:45 · Barcelona Auditorium – Hall 9 · 5 topics
  1. Optimising systemic therapy and sequence for stage I HER2-positive early breast cancer
  2. Neoadjuvant therapy for HER2+ breast cancer
  3. Endocrine therapy in early-stage HER2-positive breast cancer
  4. What to do after optimal neoadjuvant therapy?
  5. Q&A and discussion
Official Session agenda, speakers & timing ↗
Tracking genomic evolution and lineage plasticity to guide therapySun 25 Oct · 10:15–11:00 · Cordoba Auditorium – Hall 4 · 2 topics
  1. Presentation by Expert
  2. Discussion led by Chair
Official Session agenda, speakers & timing ↗
Key challenges in managing patients with metastatic breast cancerSun 25 Oct · 14:45–16:15 · Alicante Auditorium – Hall 6 · 4 topics
  1. Strategic sequencing of targeted therapies for hormonally-driven breast cancer
  2. Advancing therapies for HER2+ breast cancer: navigating a wealth of treatment options
  3. Turning the corner: personalised therapy for triple-negative breast cancer becomes a reality
  4. Q&A and discussion
Official Session agenda, speakers & timing ↗
Management of early breast cancer in young patientsMon 26 Oct · 08:30–09:15 · Granada Auditorium – Hall 4 · 2 topics
  1. Presentation by Expert
  2. Discussion led by Chair
Official Session agenda, speakers & timing ↗
Rapid oral 2: Breast cancer, advanced stageMon 26 Oct · 10:15–11:45 · Alicante Auditorium – Hall 6 · 13 topics
  1. Invited Discussant 4639RO, 4RO, 5RO and 4640RO
  2. Invited Discussant 1767RO, 1768RO and LBA49
  3. Invited Discussant 1769RO and 1770RO
  4. Q&A and discussion
  5. 4RO – Target switching with conserved-payload novel ADCs after prior ADC therapy: SWITCH
  6. 5RO – Safety and efficacy of SYS6043, a B7-H3-targeting ADC, in advanced BC
  7. 1767RO – BRIDGET: tucatinib added after isolated intracranial progression in HER2-positive BC
  8. 1768RO – Radiation therapy followed by intrathecal trastuzumab/pertuzumab in HER2+ breast leptomeningeal metastasis: INSPIRE-LM
  9. 1769RO – CTC characterization with DETECT CTC score predicts response: DETECT V translational results
  10. 1770RO – Ultra-sensitive MRD assessment in long-term complete responders to anti-HER2 therapy: HER2-CR
  11. 4639RO – Final OS analysis of sacituzumab tirumotecan versus chemotherapy: OptiTROP-Breast01
  12. 4640RO – Bulumtatug fuvedotin in previously treated locally advanced/metastatic TNBC
  13. LBA49 – DESTINY-Breast09 analysis of T-DXd + pertuzumab versus THP in HER2+ a/mBC with baseline brain metastases
Official Session agenda, speakers & timing ↗
Incorporation of biomarkers for early breast cancerMon 26 Oct · 14:45–16:15 · Almeria Auditorium – Hall 9 · 5 topics
  1. Dynamic tissue-based biomarkers to guide treatment
  2. Current use of genomic assays
  3. How to integrate new imaging techniques in the clinic
  4. MRD to inform treatment decision
  5. Q&A and discussion
Official Session agenda, speakers & timing ↗
Requested Poster & ePoster studies · 6 records

Details below are transcribed from the official ESMO 2026 Poster/ePoster records. “No scheduled display time published” means the official ePoster entry does not state a fixed presentation slot.

1890eP · ePoster · HR+ breast cancer

Integrated Molecular Profiling of Paired Tumor Tissue and Circulating Tumor DNA in Chinese Patients with HR+/HER2− Advanced Breast Cancer Prior to First-Line Systemic Therapy

Presenter: Jian Yue (Beijing, China)
Authors: Jian Yue; Liuliu Quan; Yuan Peng
Time: No scheduled display time published on the ePoster record.

314P · Poster · AI for diagnostics and profiling

Study on the association between HER2 expression in breast cancer and spatial heterogeneity of microvascular density

Presenter / author: Jingyue Li (Shenyang, China)
Time: Sun 25 Oct 2026 · 12:00–12:45

1907eP · ePoster · HR+ breast cancer

Real-World Effectiveness and Safety of the Novel Agent Inavolisib in Heavily Pretreated, PIK3CA-mut Advanced Breast Cancer: A Multicenter Study of Patients with More Advanced and Complex Disease

Presenter: Xu Liang (Beijing, China)
Authors: Xu Liang; Yong Pan; Mopei Wang; Huiping Li; Guohong Song
Time: No scheduled display time published on the ePoster record.

1841eTiP · ePoster · HER2+ breast cancer

Al18F-HER2-BCH PET/CT guided precision neoadjuvant therapy for HER2-positive early breast cancer: FHERNAT trial

Presenter: Xu Liang (Beijing, China)
Authors: Xu Liang; Yifei Chen; Xiaoyi Guo
Time: No scheduled display time published on the ePoster record.

1779P · Poster · HER2+ breast cancer

Prognostic Impact of PIK3CA Mutations in HER2-Positive Advanced Breast Cancer: A Real-World Multicenter Study

Presenter: Ouchen Wang (Wenzhou, China)
Authors: Ouchen Wang; Jingao Dai; Wenwu Wang; Guobin Jiang; Zhengyang Xu; Guinv Hu; Chaoyue Lv; Shengnan Yao; Jiatong Ru
Time: Sat 24 Oct 2026 · 12:00–12:45

1929eP · ePoster · HR+ breast cancer

Characterization of PIK3CA variants and real-world clinical evolution of first-line CDK4/6 inhibitors: Insights from a Chinese HR+/HER2− advanced breast cancer cohort

Presenter / author: Shi Jing (Shenyang, China)
Time: No scheduled display time published on the ePoster record.

Thu · 22 Oct

CEST
17:30
ROCHE EVENT
BC Affiliate Briefing
17:30–18:45 · Zaragoza meeting room, Melia Avenida de América · Virtual attendance available

Fri · 23 Oct

CEST
09:45
SATELLITE
Medscape: Redrawing the Breast Cancer Roadmap
Pamplona Auditorium – Hall 5
13:30
Invasive lobular carcinoma: Detecting and managing an elusive enemy
Cordoba Auditorium – Hall 4
13:30
Proffered paper 1: Breast cancer, early and advanced stage
Alicante Auditorium – Hall 6
16:15
Rapid oral: Breast cancer, early stage
Alicante Auditorium – Hall 6
18:15
SATELLITEHR+ RELATED
Menarini: ESR1-mutated Advanced Breast Cancer
Santander Auditorium – Hall 10
18:15
SATELLITEHR+ RELATED
F. Hoffmann-La Roche: From evidence to action in HR+, HER2− mBC
Madrid Auditorium – Hall 4
View official satellite invitation

Fri, 23 Oct 2026 · 18:15–19:45 CEST
Madrid Auditorium, Hall 4 · IFEMA Madrid

Official invitation ↗

Sat · 24 Oct

CEST
08:30
Proffered paper 2: Breast cancer, early and advanced stage
Alicante Auditorium – Hall 6
10:15
Rapid oral 1: Breast cancer, advanced stage
Almeria Auditorium – Hall 9
13:00
SATELLITE
AstraZeneca: Advancing 1L Breast Cancer Care Across Subtypes
Granada Auditorium – Hall 4
14:45
Optimising treatment for triple negative early breast cancer
Almeria Auditorium – Hall 9
16:30
Novel concepts for metastatic breast cancer: Looking to the future
Barcelona Auditorium – Hall 9
16:30
ROCHE EVENT
Dr Chen, Claus visit
Location TBC
18:30
SATELLITEHR+ RELATED
Eli Lilly: HR+/HER2− Breast Cancer—Defining Your Next Clinical Direction
Madrid Auditorium – Hall 4

Sun · 25 Oct

CET
08:30
HR+ RELATED
Personalising treatment for patients with early stage HR+ breast cancer
Bilbao Auditorium – Hall 3
10:15
Optimising treatment for HER2+ early breast cancer
Barcelona Auditorium – Hall 9
10:15
Tracking genomic evolution and lineage plasticity to guide therapy
Cordoba Auditorium – Hall 4
12:00
SATELLITE
Daiichi Sankyo/AstraZeneca: ADC patient journey in advanced breast cancer care
Segovia Auditorium – Palacio Municipal
13:00
SATELLITEHR+ RELATED
F. Hoffmann-La Roche: HR+/HER2− early breast cancer endocrine therapy
Granada Auditorium – Hall 4
View official satellite agenda

Next-era strategies in HR+ HER2− early breast cancer: Optimising endocrine therapy

Sun, 25 Oct 2026 · 13:00–14:30 CET
Granada Auditorium, Hall 4 · IFEMA Madrid

  1. Welcome and introduction — Nicholas C. Turner
  2. Current adjuvant endocrine-based therapies and unmet needs in patient care — Nicholas C. Turner
  3. Evaluating oral SERDs in adjuvant endocrine therapy: Current evidence and clinical trials — Miguel Martín
  4. Exploring window-of-opportunity trials and ctDNA-based approaches to further optimise the early stage setting with oral SERDs — Erica L. Mayer
  5. Q&A and discussion — All presenters

For Healthcare Professionals registered to attend ESMO 2026. The symposium is also available via livestream.

Official invitation ↗
14:45
Key challenges in managing patients with metastatic breast cancer
Alicante Auditorium – Hall 6
16:30
Pillars of personalised cancer prevention: The breast cancer case
Cadiz Auditorium – NCC
18:00
ROCHE EVENT
Giredestrant Internal Launch Apéro
18:00–20:00 · La Sala, Florida Park
18:30
SATELLITE
Gilead/Kite: The ADC Evolution in Breast and Gynaecologic Cancers
Malaga Auditorium – Hall 3
18:30
SATELLITE
Pfizer: Metastatic Breast Cancer—Individualised Decision-Making
Madrid Auditorium – Hall 4

Mon · 26 Oct

CET
08:30
Management of early breast cancer in young patients
Granada Auditorium – Hall 4
10:15
Rapid oral 2: Breast cancer, advanced stage
Alicante Auditorium – Hall 6
11:30
ROCHE EVENT
Dr Li Clause visit
11:30–12:00 · Location TBC
13:00
SATELLITEHR+ RELATED
Novartis: CDK4/6 strategies in HR+/HER2− breast cancer
Madrid Auditorium – Hall 4
14:45
Incorporation of biomarkers for early breast cancer
Almeria Auditorium – Hall 9